-
公开(公告)号：US09770601B2
公开(公告)日：2017-09-26
申请号：US14714368
申请日：2015-05-18
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Elisha Moses , Assaf Rotem
CPC classification number: A61N2/006 , A61B5/0484 , A61B5/4836 , A61N1/08 , A61N1/36025 , A61N1/36082 , A61N1/40 , A61N2/02
Abstract: Transcranial magnetic stimulation (TMS) is a remarkable tool for probing the brain. However, it is still unclear why specific regions in the cortex are excitable by TMS while others are not. This invention provides methods and tools for the design of efficient magnetic stimulators. Such stimulators can excite neuronal networks that were not sensitive to stimulation until now. Stimulation can be carried out both in-vitro and in-vivo. Novel systems and techniques of this invention will enable both treatment and diagnostics by stimulating regions of the brain or neuronal assemblies that were previously unaffected by TMS.
-
公开(公告)号：US20170247468A1
公开(公告)日：2017-08-31
申请号：US15494585
申请日：2017-04-24
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Deborah FASS , Iris GROSSMAN , Tal ILANI , Assaf ALON
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K2299/00 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N15/1137 , C12N2310/14 , C12Y108/03002
Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.
-
公开(公告)号：US20170206308A1
公开(公告)日：2017-07-20
申请号：US15323994
申请日：2015-07-06
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Sarel FLEISHMAN , Gideon LAPIDOTH , Maria Gabriele PSZOLLA , Christoffer NORN
Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.
-
公开(公告)号：US20170196888A1
公开(公告)日：2017-07-13
申请号：US15321281
申请日：2015-06-25
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef YARDEN , Mattia LAURIOLA
IPC: A61K31/573 , A61K9/00 , A61K31/517
CPC classification number: A61K31/573 , A61K9/0053 , A61K31/517 , A61K45/06 , A61K2300/00
Abstract: A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a receptor tyrosine kinase (RTK)-specific cancer therapy and a glucocorticoid or a glucocorticoid analog, such that an efficacy window of said RTK-specific cancer therapy and an efficacy window of said glucocorticoid or glucocorticoid analog substantially overlap.
-
公开(公告)号：US20170175127A1
公开(公告)日：2017-06-22
申请号：US15442784
申请日：2017-02-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef SHAUL , Peter TSVETKOV , Julia ADLER
IPC: C12N15/113
CPC classification number: C12N15/1137 , A61K31/713 , C12N15/1135 , C12N2310/14 , C12Q1/025 , C12Q1/68 , G01N33/5011 , G01N2333/4703 , G01N2500/04 , G01N2500/10
Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.
-
Patent Agency Ranking
公开(公告)号：US20170174764A1
公开(公告)日：2017-06-22
申请号：US15127023
申请日：2015-03-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irun R. COHEN , Nir FRIEDMAN , Asaf MADI , Eric SHIFRUT , Shlomit REICH-ZELIGER , Asaf PORAN
IPC: C07K16/28
CPC classification number: C07K16/2809 , A61K39/0008 , A61K2039/505
Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.
-
公开(公告)号：US09685619B2
公开(公告)日：2017-06-20
申请号：US14413885
申请日：2013-07-09
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Milko E. Van Der Boom , Graham De Ruiter
CPC classification number: H01L51/0088 , H01L27/28 , H01L51/0067 , H01L51/0595 , H03K19/20 , H03K19/21
Abstract: A logic circuit for performing a logic operation comprising a plurality of predetermined solid-state molecular chips, each molecular chip having multiple states obtained after application of a corresponding input. After applying predetermined inputs on the molecular chips, reading the states of the molecular chips produces a logical output according to the logic operation.
-
738.发明申请公开(公告)号：US20170165285A1
公开(公告)日：2017-06-15
申请号：US15438806
申请日：2017-02-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef YARDEN , Nir BEN-CHETRIT
IPC: A61K31/7048 , C07K16/30 , A61K31/366 , A61K31/7034 , A61K31/353 , A61K31/05 , A61K31/12 , A61K31/7032 , A61K31/155 , A61K31/4709 , A61K31/216 , A61K31/235 , A61K38/17 , A61K31/704
CPC classification number: A61K31/7048 , A61K31/05 , A61K31/12 , A61K31/155 , A61K31/216 , A61K31/235 , A61K31/353 , A61K31/366 , A61K31/4709 , A61K31/7032 , A61K31/7034 , A61K31/704 , A61K38/179 , A61K39/0011 , A61K45/06 , C07K16/30 , G01N33/57415 , A61K2300/00
Abstract: A method of preventing tumor metastasis with the proviso that the tumor is not glioma is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2), thereby preventing tumor metastasis. Also, provided is a method of treating cancer. The method comprising, administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2) and an inhibitor of a cell surface receptor associated with an onset or progression of cancer, thereby treating cancer.
-
公开(公告)号：US20170143988A1
公开(公告)日：2017-05-25
申请号：US15425473
申请日：2017-02-06
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Avigdor Scherz , Alexander Brandis , Ohad Mazor , Yoram Salomon , Hugo Scheer
CPC classification number: A61N5/062 , A61F9/0008 , A61K31/40 , A61K41/0071 , A61K41/0076 , A61K49/0036 , A61N5/0624 , C07F1/08 , C07F3/02 , C07F3/06 , C07F13/005 , C07F15/006 , C07F15/0066 , C07F15/045
Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.
-
740.发明申请公开(公告)号：US20170122950A1
公开(公告)日：2017-05-04
申请号：US15358162
申请日：2016-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Moshit Lindzen , Yosef Yarden
IPC: G01N33/574 , G01N33/577 , C07K16/22
CPC classification number: G01N33/57484 , A61K31/7068 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K2317/73 , C07K2317/76 , G01N33/5011 , G01N33/57423 , G01N33/57438 , G01N33/57492 , G01N33/577 , G01N2333/485 , G01N2333/495 , G01N2500/00 , A61K2300/00
Abstract: A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
1003
records
(took 0.05 seconds)
